Square Garden Pharmaceutical

Square Garden Pharmaceutical is a clinical-stage biopharmaceutical company based in China that focuses on the development of innovative small molecule therapeutics for oncology and endocrine-related diseases. The company's primary research efforts are centered on targeting nuclear receptors, particularly the androgen receptor, to treat advanced malignancies such as castration-resistant prostate cancer. Their lead candidate, SG001, is an androgen receptor antagonist designed to overcome resistance mechanisms seen in traditional therapies. Square Garden aims to provide more effective and safer treatment options for patients with high unmet medical needs in the oncology space.